Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Change in Accured Expenses of $43372.0 for Q1 2026, down 94.79% year-over-year from $833219.0 in Q1 2025, and down 89.79% quarter-over-quarter from $424899.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Change in Accured Expenses for 7 consecutive years, with $43372.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 94.79% year-over-year to $43372.0; the TTM figure through Mar 2026 stood at $611405.0 (down 39.2% YoY), while the FY2025 annual figure was $1.4 million, up 233.57% from the prior year.
- Change in Accured Expenses fell to $43372.0 in Q1 2026 per IKT's latest filing, from $424899.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $858240.0 in Q1 2022 and bottomed at -$1.3 million in Q3 2022.
- Historically, Change in Accured Expenses has averaged $82876.1 across 5 years, with a median of $132394.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 15605.69% — and 2024, when it tumbled 273.47%.
- Inhibikase Therapeutics' Change in Accured Expenses stood at $132394.0 in 2022, then soared by 203.44% to $401740.0 in 2023, then grew by 29.1% to $518656.0 in 2024, then slipped by 18.08% to $424899.0 in 2025, then plunged by 89.79% to $43372.0 in 2026.
- Business Quant data shows IKT's Change in Accured Expenses at $43372.0 in Q1 2026, $424899.0 in Q4 2025, and $718197.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 5.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.14 Mn |
| Jun 30, 2026 | 5.14 Mn |
| Mar 31, 2026 | 43,372.00 |
| Mar 31, 2026 | 43,372.00 |
| Dec 31, 2025 | 424,899.00 |
| Dec 31, 2025 | 424,899.00 |
| Sep 30, 2025 | 718,197.00 |
| Sep 30, 2025 | 718,197.00 |
| Jun 30, 2025 | -575,063.00 |
| Jun 30, 2025 | -575,063.00 |
| Mar 31, 2025 | 833,219.00 |
| Mar 31, 2025 | 833,219.00 |
| Dec 31, 2024 | 518,656.00 |
| Dec 31, 2024 | 518,656.00 |
| Sep 30, 2024 | 126,849.00 |
| Sep 30, 2024 | 126,849.00 |
| Jun 30, 2024 | -473,064.00 |
| Jun 30, 2024 | -473,064.00 |
| Mar 31, 2024 | 247,634.00 |
| Mar 31, 2024 | 247,634.00 |